Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/51101
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2020-01-31T07:17:19Z | - |
dc.date.available | 2020-01-31T07:17:19Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | Attard, A., Cilia, M., Zammit, M. C., Wirth, F., Coleiro, B., Zarb Adami, M.,…Serracino-Inglott, A. (2010, March). Bioequivalence of doxazosin slow release tablets: a pilot study. Poster session presented at the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valletta, Malta. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/51101 | - |
dc.description.abstract | A poster presentation regarding a pilot study on the bioequivalence of doxazosin slow release tablets. Introduction: Bioequivalence studies are carried out to compare the systemic exposure profile of a test drug product to that of a reference product. Doxazosin is a potent quinazoline derivative and is effective for the treatment of hypertension and benign prostatic hyperplasia. Aim: To carry out a pilot bioequivalence study to assess comparative bioavailability between test product, doxazosin mesylate 8mg slow release tablets and reference product, Cardura®XL 8mg tablets. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | University of Malta. Department of Pharmacy | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Drugs -- Therapeutic equivalency | en_GB |
dc.subject | Doxazosin -- Analysis | en_GB |
dc.subject | Doxazosin -- Therapeutic use | en_GB |
dc.subject | High performance liquid chromatography -- Methodology | en_GB |
dc.title | Bioequivalence of doxazosin slow release tablets : a pilot study | en_GB |
dc.type | presentation | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | N/A | en_GB |
dc.contributor.creator | Attard, Alison | - |
dc.contributor.creator | Cilia, Mark | - |
dc.contributor.creator | Zammit, Marie Clare | - |
dc.contributor.creator | Wirth, Francesca | - |
dc.contributor.creator | Coleiro, Bernard | - |
dc.contributor.creator | Zarb Adami, Maurice | - |
dc.contributor.creator | Azzopardi, Lilian M. | - |
dc.contributor.creator | Serracino-Inglott, Anthony | - |
Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bioequivalence_of_doxazosin_slow_release_tablets_a_pilot_study_2010.pdf | 1.1 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.